Alumis, Inc.
Alumis Inc. is dedicated to transforming the lives of patients with immune-mediated diseases through a precision approach to develop targeted oral therapies. Their mission is to replace broad immunosuppression with precise, effective treatments, leveraging powerful data analytics and genetic insights to optimize therapeutic outcomes. Led by a team of experienced drug developers, Alumis aims to produce the next generation of treatments that address immune dysfunction and improve patient quality of life.
Industries
Nr. of Employees
small (1-50)
Alumis, Inc.
Products
ESK-001
An investigational oral, highly selective TYK2 small-molecule inhibitor in clinical development for moderate-to-severe plaque psoriasis (Phase 3) and systemic lupus erythematosus (Phase 2b).
A-005
A CNS‑penetrant, allosteric TYK2 small-molecule inhibitor designed for neuroinflammatory and neurodegenerative indications; completed Phase 1 in healthy volunteers and planned to enter Phase 2 for multiple sclerosis.
ESK-001
An investigational oral, highly selective TYK2 small-molecule inhibitor in clinical development for moderate-to-severe plaque psoriasis (Phase 3) and systemic lupus erythematosus (Phase 2b).
A-005
A CNS‑penetrant, allosteric TYK2 small-molecule inhibitor designed for neuroinflammatory and neurodegenerative indications; completed Phase 1 in healthy volunteers and planned to enter Phase 2 for multiple sclerosis.
Services
Precision data analytics platform (internal)
Integrated analytics platform that leverages curated genetic, genomic, proteomic and clinical data to inform target selection, trial design, patient stratification and endpoint selection.
Precision data analytics platform (internal)
Integrated analytics platform that leverages curated genetic, genomic, proteomic and clinical data to inform target selection, trial design, patient stratification and endpoint selection.
Expertise Areas
- Clinical trial management (Phase 1–3)
- Precision data analytics for target and indication selection
- Small-molecule kinase inhibitor discovery
- Biomarker discovery and translational science
Key Technologies
- TYK2 small-molecule inhibition
- Allosteric kinase inhibition
- CNS-penetrant small-molecule design
- Integrated genomics-proteomics-clinical data analytics